Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by measuring circulating tumour DNA

Bookmark and Share
Published: 15 Dec 2020
Views: 146
Rating:
Save
Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Dr Alex Herrera speaks to ecancer about risk profiling of r/r diffuse large B-Cell lymphoma patients by measuring circulating tumour DNA.

This was presented at this year’s virtual ASH 2020 meeting. Initially Dr Herrera speaks to ecancer about what the study evaluated and hen moves on to explain the methodology of the study.

Whilst explaining the results he says that the baseline ctDNA levels were correlated with standard clinical risk factors, and were shown to have independent prognostic value for response, PFS and OS in R/R DLBCL patients treated with BR /- pola.

Dr Herrera says that this provides early evidence that ctDNA can be used to improve identification of R/R DLBCL patients at high risk for disease progression/relapse.

In the end, he talks about how these results can be beneficial for future diagnosis and treatment of large B-cell lymphoma.